(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 63.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.86%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.25%.
X4 Pharmaceuticals's revenue in 2026 is $15,847,000.On average, 7 Wall Street analysts forecast XFOR's revenue for 2026 to be $1,616,091,911, with the lowest XFOR revenue forecast at $1,408,875,218, and the highest XFOR revenue forecast at $1,801,000,587. On average, 7 Wall Street analysts forecast XFOR's revenue for 2027 to be $1,169,039,247, with the lowest XFOR revenue forecast at $631,564,753, and the highest XFOR revenue forecast at $1,801,000,587.
In 2028, XFOR is forecast to generate $8,062,613,141 in revenue, with the lowest revenue forecast at $1,651,784,738 and the highest revenue forecast at $19,113,509,116.